Workflow
Compared to Estimates, Embraer (ERJ) Q2 Earnings: A Look at Key Metrics
ZACKS· 2025-08-05 23:01
Embraer (ERJ) reported $1.82 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 21.8%. EPS of -$0.02 for the same period compares to $0.44 a year ago.The reported revenue represents a surprise of +8.88% over the Zacks Consensus Estimate of $1.67 billion. With the consensus EPS estimate being $0.47, the EPS surprise was -104.26%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street exp ...
Bitfarms Ltd. (BITF) Expected to Beat Earnings Estimates: Should You Buy?
ZACKS· 2025-08-05 23:01
The market expects Bitfarms Ltd. (BITF) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 12, might help the stock move higher if these key numbers are bette ...
Earnings Preview: Cava Group (CAVA) Q2 Earnings Expected to Decline
ZACKS· 2025-08-05 23:01
The market expects Cava Group (CAVA) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...
Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?
ZACKS· 2025-08-05 23:01
公司业绩预期 - Inovio Pharmaceuticals预计在2025年6月季度报告中每股亏损0.63美元,同比改善47.1%,但营收预计为5万美元,同比下降50% [3] - 过去30天内,分析师将共识EPS预期上调4.55%,反映对业绩前景的重新评估 [4] - 公司最近四个季度中有三次超过EPS预期,最近一次季度实际亏损0.51美元,比预期亏损0.74美元高出31.08%的正面意外 [12][13] 业绩预测模型 - Zacks Earnings ESP模型通过比较最准确估计与共识估计来预测业绩意外,最准确估计包含分析师最新信息 [7] - 对于Inovio,最准确估计高于共识估计,产生+10.76%的ESP值,结合Zacks Rank 3,显示很可能超过EPS预期 [11] - 历史数据显示,具有正ESP和Zacks Rank 1-3的股票有近70%概率实现业绩超预期 [9] 行业比较 - 同行业公司VistaGen Therapeutics预计季度每股亏损0.47美元,同比下降34.3%,但营收预计65万美元,同比大增712.5% [17][18] - VistaGen过去30天共识EPS预期上调4.9%,但ESP为-3.52%,结合Zacks Rank 3,难以预测其将超过预期 [18][19] - VistaGen过去四个季度中也有三次超过EPS预期 [19] 市场影响 - 实际业绩与预期的对比将显著影响Inovio短期股价,超预期可能推动股价上涨,不及预期则可能导致下跌 [1][2] - 业绩电话会上管理层对业务状况的讨论将决定股价变动的持续性和未来盈利预期 [2] - 虽然业绩超预期是重要因素,但其他催化剂也可能导致股价与业绩表现背离 [14][15]
Pfizer Stock Pops on Q2 Beat-and-Raise
Schaeffers Investment Research· 2025-08-05 23:01
The shares of Pfizer Inc (NYSE:PFE) were last seen up 4.9% to trade at $24.4, after the pharmaceutical giant's second-quarter results beat expectations. The company also lifted its 2025 profit outlook, citing strength for its Covid-19 drugs as well as its Vyndaqel heart medication.Pfizer was one of the 17 companies President Donald Trump wrote to demanding lower drug prices. The firm said its current guidance absorbs the cost of tariffs and cost-cutting measures. In other news, the company will also abandon ...
On Holding (ONON) Reports Next Week: Wall Street Expects Earnings Growth
ZACKS· 2025-08-05 23:01
核心观点 - 华尔街预计On Holding在2025年第二季度将实现收入和盈利同比增长,关键数据与预期的对比将影响股价短期走势[1][2] - 公司预计每股收益0.24美元(同比+50%),收入8.4521亿美元(同比+34.7%)[3] - 尽管近期分析师上调盈利预期导致盈利ESP达+8.51%,但Zacks Rank 4评级使盈利超预期预测存在不确定性[12] - 公司过去四个季度仅一次超预期,上一季度实际EPS 0.23美元(低于预期4.17%)[13][14] 财务预期 - 共识EPS预估在过去30天内被下调3.01%,反映分析师对业务条件的重新评估[4] - Zacks盈利ESP模型显示,当Most Accurate Estimate高于共识时,实际盈利超预期概率提升(历史准确率70%)[8][10] 历史表现与市场反应 - 过去盈利不及预期的主因可能来自管理层在电话会议中讨论的业务条件[2] - 股价变动不仅取决于盈利是否超预期,还受其他未预见催化剂或利空因素影响[15][16] 当前投资逻辑 - 公司当前盈利预期与分析师近期乐观修正存在分歧,需结合Zacks Rank和ESP综合判断[12] - 投资者需关注8月12日财报发布后的业务讨论,而非单纯依赖盈利是否超预期[17]
Sky Harbour Group Corporation (SKYH) Expected to Beat Earnings Estimates: Should You Buy?
ZACKS· 2025-08-05 23:01
核心观点 - Sky Harbour Group预计在2025年6月季度报告中营收增长但盈利同比下降,市场共识预期季度每股亏损0.12美元,同比变化-300%,营收预计663万美元,同比增长83.2% [1][3] - 公司股票价格可能因财报结果超预期或低于预期而波动,财报发布日期为8月12日 [2] - 公司当前Zacks Rank为1(强力买入),且盈利ESP为+35.13%,显示分析师近期对其盈利前景持乐观态度,大概率超预期 [12] 财务预期与修订 - 过去30天内,季度每股亏损共识预期上调13.33%,反映分析师对初始预期的集体修正 [4] - 公司上一季度实际每股亏损0.11美元,优于预期的0.25美元,意外惊喜达+56.00% [13] - 过去四个季度中,公司两次超预期 [14] 行业比较 - 同行业公司Mercury Systems预计季度每股收益0.21美元,同比下滑8.7%,营收预计2.4171亿美元,同比下滑2.8% [18][19] - Mercury Systems盈利ESP为+8.05%,但Zacks Rank为5(强力卖出),难以预测其能否超预期,过去四个季度三次超预期 [19][20] 盈利预测模型 - Zacks盈利ESP模型通过比较最新修正的“最准确估计”与共识预期,预测实际盈利偏离方向,正ESP对预测有显著意义 [7][8][9] - 盈利ESP与Zacks Rank结合(1-3级)时,超预期概率近70% [10] - 负ESP或低Zacks Rank(4-5级)难以预测盈利超预期 [11] 其他影响因素 - 盈利超预期或低于预期并非股价波动的唯一因素,其他催化剂或利空可能影响结果 [15] - 尽管Sky Harbour Group盈利超预期概率高,但投资者仍需关注其他因素 [17]
Wix Rolls Out New Financial Services for Small Business Growth
ZACKS· 2025-08-05 22:56
公司动态 - Wix推出全新金融服务套件Wix Checking和Wix Capital 旨在简化现金流管理并助力小型企业在平台内实现无缝增长 [1] - Wix Checking为符合条件的用户提供完全集成的商业支票账户 实时查看收支情况 销售收益即时可用 无需第三方银行工具或手动记账 [2] - Wix Capital提供商户现金预支(MCA)解决方案 通过固定费用和收入比例还款方式快速获取资金 用于库存、薪资或运营投资等需求 [3] - 目前Wix Checking和Wix Capital仅面向使用Wix Payments的美国用户 未来计划扩大覆盖范围 服务由林肯储蓄银行提供 [4] 技术发展 - 公司持续战略投资AI产品 2025年7月16日推出AI Visibility Overview工具 帮助网站在大型语言模型(如ChatGPT、Gemini)中优化数字发现 [5] - 近期扩大与PayPal合作 将PayPal Business账户直接集成至Wix Payments 商户可通过单一仪表盘管理所有交易、拒付和付款 [6] 财务表现 - 公司计划于2025年8月6日开盘前发布第二季度财报 [6] - 过去一年公司股价下跌16.3% 同期计算机-IT服务行业跌幅为1.7% [7] 行业对比 - CDW Corporation过去四个季度两次盈利超预期 平均惊喜幅度2.09% 最近季度达9.69% 股价过去一年下跌17.4% [11] - ExlService Holdings过去四个季度均盈利超预期 平均惊喜幅度7.55% 最近季度8.89% 股价过去一年上涨24.7% [12] - Genpact Limited过去四个季度均盈利超预期 平均惊喜幅度6.32% 最近季度5% 股价过去一年上涨31.6% [12]
Bears are Losing Control Over Sensata (ST), Here's Why It's a 'Buy' Now
ZACKS· 2025-08-05 22:56
股价趋势 - Sensata股价近期呈下跌趋势 过去一周下跌84% [1] - 最近交易时段形成锤形图表模式 显示可能出现趋势反转 多头可能已取得价格控制权并找到支撑位 [1] 技术分析 - 锤形模式是技术指标 显示可能接近底部且卖压耗尽 [2] - 锤形由微小实体和长下影线组成 下影线长度至少为实体两倍 形似锤子 [4] - 该模式出现在下跌趋势底部时 表明空头可能失去价格控制权 多头成功阻止进一步下跌预示趋势反转 [5] - 锤形可用于任何时间框架 包括一分钟图/日线图/周线图 适合长短线投资者 [5] - 该模式需结合其他看涨指标使用 因其强度取决于图表位置 [6] 基本面因素 - 华尔街分析师对这家传感器/电气保护/控制/电源管理产品制造商的未来盈利持乐观态度 增强趋势反转可能性 [2] - 盈利预测修正呈上升趋势 与短期股价走势高度相关 [7] - 当前年度共识EPS预测在过去30天增长3% 显示分析师普遍上调盈利预期 [8] 评级与市场表现 - 公司目前获Zacks Rank 2级(买入) 位列4000多只股票前20% 该排名基于盈利预测修正和EPS意外 [9] - Zacks Rank 1或2级股票通常跑赢大盘 [9] - Zacks Rank 2级是趋势反转的更明确指标 因其能精准识别公司前景改善时机 [10]
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade
ZACKS· 2025-08-05 22:56
Shares of Ikena Oncology, Inc. (IMA) have gained 2.4% over the past four weeks to close the last trading session at $16.6, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $132.05 indicates a potential upside of 695.5%.The mean estimate comprises three short-term price targets with a standard deviation of $125.33. While the lowest estimate of $48.02 indicates an 189.3% increase f ...